Peringatan Keamanan

Oral LD50 is 2000 mg/kg in rats, 1870 mg/kg in mice, and 500 mg/kg in dog.L42905

In case of overdosage, doxycycline should be discontinued and symptomatic and supportive treatment should be initiated. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.L42870

Doxycycline

DB00254

small molecule approved investigational vet_approved

Deskripsi

Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.L42880 It is a second-generation tetracycline that was first discovered in 1967.A19429 Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines.A174034 Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.A251730

Struktur Molekul 2D

Berat 444.4346
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) There is limited information available.
Volume Distribusi There is limited information available.
Klirens (Clearance) Population pharmacokinetic analysis of sparse concentration-time data of doxycycline following standard of care intravenous and oral dosing in 44 pediatric patients two to 18 years of age showed allometrically -scaled clearance (CL) ranging from 3.27 to 3.58 L/h/70 kg.[L42880]

Absorpsi

Doxycycline is virtually completely absorbed after oral administration L42870 with a bioavailability of ranging from 73-95%.A1424 Following an oral dose of 500 mg, the Cmax of 15.3 mg/L was reached in four hours.A1424 Following a 200 mg dose, normal adult volunteers averaged peak serum levels of 2.6 mcg/mL of doxycycline at 2 hours, decreasing to 1.45 mcg/mL at 24 hours.L42880 While a high-fat meal lowers Cmax and the rate of absorption, the effect is not clinically significant.L42870

Metabolisme

There is limited information available.

Rute Eliminasi

Tetracyclines, including doxycycline, are concentrated in bile by the liver and excreted in the urine and feces at high concentrations and in a biologically active form.L42870 Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with a creatinine clearance of about 75 mL/min. This percentage may fall as low as 1-5%/72 hours in individuals with a creatinine clearance below 10 mL/min.L42870

Interaksi Makanan

2 Data
  • 1. Avoid multivalent ions. The absorption of tetracyclines is reduced when taken with foods, especially those which contain calcium.
  • 2. Take with or without food. The absorption of tetracyclines is reduced when taken with foods, but not to a significant extent. If gastric irritation occurs, it is recommended that doxycycline be given with food or milk.

Interaksi Obat

1093 Data
Succinylcholine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Doxycycline.
Metocurine iodide The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Doxycycline.
Gallamine triethiodide The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Doxycycline.
Cisatracurium Doxycycline may increase the neuromuscular blocking activities of Cisatracurium.
Rocuronium The therapeutic efficacy of Rocuronium can be increased when used in combination with Doxycycline.
Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Doxycycline.
Doxacurium The therapeutic efficacy of Doxacurium can be increased when used in combination with Doxycycline.
Mivacurium The therapeutic efficacy of Mivacurium can be increased when used in combination with Doxycycline.
Decamethonium The therapeutic efficacy of Decamethonium can be increased when used in combination with Doxycycline.
Metocurine The therapeutic efficacy of Metocurine can be increased when used in combination with Doxycycline.
Pancuronium The therapeutic efficacy of Pancuronium can be increased when used in combination with Doxycycline.
Pipecuronium The therapeutic efficacy of Pipecuronium can be increased when used in combination with Doxycycline.
Vecuronium The therapeutic efficacy of Vecuronium can be increased when used in combination with Doxycycline.
Rapacuronium The therapeutic efficacy of Rapacuronium can be increased when used in combination with Doxycycline.
Pyrantel The therapeutic efficacy of Pyrantel can be increased when used in combination with Doxycycline.
Neosaxitoxin The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Doxycycline.
Atracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Doxycycline.
Gallamine The therapeutic efficacy of Gallamine can be increased when used in combination with Doxycycline.
Alcuronium The therapeutic efficacy of Alcuronium can be increased when used in combination with Doxycycline.
Tubocurarine The therapeutic efficacy of Tubocurarine can be increased when used in combination with Doxycycline.
Butalbital The serum concentration of Doxycycline can be decreased when it is combined with Butalbital.
Pentobarbital The serum concentration of Doxycycline can be decreased when it is combined with Pentobarbital.
Secobarbital The serum concentration of Doxycycline can be decreased when it is combined with Secobarbital.
Methohexital The serum concentration of Doxycycline can be decreased when it is combined with Methohexital.
Thiopental The serum concentration of Doxycycline can be decreased when it is combined with Thiopental.
Primidone The serum concentration of Doxycycline can be decreased when it is combined with Primidone.
Methylphenobarbital The serum concentration of Doxycycline can be decreased when it is combined with Methylphenobarbital.
Thiamylal The serum concentration of Doxycycline can be decreased when it is combined with Thiamylal.
Phenobarbital The serum concentration of Doxycycline can be decreased when it is combined with Phenobarbital.
Amobarbital The serum concentration of Doxycycline can be decreased when it is combined with Amobarbital.
Hexobarbital The serum concentration of Doxycycline can be decreased when it is combined with Hexobarbital.
Barbital The serum concentration of Doxycycline can be decreased when it is combined with Barbital.
Barbexaclone The serum concentration of Doxycycline can be decreased when it is combined with Barbexaclone.
Butabarbital The serum concentration of Doxycycline can be decreased when it is combined with Butabarbital.
Phenytoin The serum concentration of Doxycycline can be decreased when it is combined with Phenytoin.
Fosphenytoin The serum concentration of Doxycycline can be decreased when it is combined with Fosphenytoin.
Bismuth subsalicylate The serum concentration of Doxycycline can be decreased when it is combined with Bismuth subsalicylate.
Mecamylamine Doxycycline may increase the neuromuscular blocking activities of Mecamylamine.
Mipomersen Doxycycline may increase the hepatotoxic activities of Mipomersen.
Quinapril Quinapril can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sucralfate Sucralfate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron sucrose The serum concentration of Doxycycline can be decreased when it is combined with Iron sucrose.
Flucloxacillin The therapeutic efficacy of Flucloxacillin can be decreased when used in combination with Doxycycline.
Piperacillin The therapeutic efficacy of Piperacillin can be decreased when used in combination with Doxycycline.
Ampicillin The therapeutic efficacy of Ampicillin can be decreased when used in combination with Doxycycline.
Phenoxymethylpenicillin The therapeutic efficacy of Phenoxymethylpenicillin can be decreased when used in combination with Doxycycline.
Dicloxacillin The therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Doxycycline.
Carbenicillin The therapeutic efficacy of Carbenicillin can be decreased when used in combination with Doxycycline.
Nafcillin The therapeutic efficacy of Nafcillin can be decreased when used in combination with Doxycycline.
Oxacillin The therapeutic efficacy of Oxacillin can be decreased when used in combination with Doxycycline.
Hetacillin The therapeutic efficacy of Hetacillin can be decreased when used in combination with Doxycycline.
Benzylpenicilloyl polylysine The therapeutic efficacy of Benzylpenicilloyl polylysine can be decreased when used in combination with Doxycycline.
Mezlocillin The therapeutic efficacy of Mezlocillin can be decreased when used in combination with Doxycycline.
Cyclacillin The therapeutic efficacy of Cyclacillin can be decreased when used in combination with Doxycycline.
Benzylpenicillin The therapeutic efficacy of Benzylpenicillin can be decreased when used in combination with Doxycycline.
Amoxicillin The therapeutic efficacy of Amoxicillin can be decreased when used in combination with Doxycycline.
Azlocillin The therapeutic efficacy of Azlocillin can be decreased when used in combination with Doxycycline.
Cloxacillin The therapeutic efficacy of Cloxacillin can be decreased when used in combination with Doxycycline.
Amdinocillin The therapeutic efficacy of Amdinocillin can be decreased when used in combination with Doxycycline.
Bacampicillin The therapeutic efficacy of Bacampicillin can be decreased when used in combination with Doxycycline.
Meticillin The therapeutic efficacy of Meticillin can be decreased when used in combination with Doxycycline.
Pivampicillin The therapeutic efficacy of Pivampicillin can be decreased when used in combination with Doxycycline.
Pivmecillinam The therapeutic efficacy of Pivmecillinam can be decreased when used in combination with Doxycycline.
Ticarcillin The therapeutic efficacy of Ticarcillin can be decreased when used in combination with Doxycycline.
Azidocillin The therapeutic efficacy of Azidocillin can be decreased when used in combination with Doxycycline.
Carindacillin The therapeutic efficacy of Carindacillin can be decreased when used in combination with Doxycycline.
Procaine benzylpenicillin The therapeutic efficacy of Procaine benzylpenicillin can be decreased when used in combination with Doxycycline.
Sultamicillin The therapeutic efficacy of Sultamicillin can be decreased when used in combination with Doxycycline.
Temocillin The therapeutic efficacy of Temocillin can be decreased when used in combination with Doxycycline.
Epicillin The therapeutic efficacy of Epicillin can be decreased when used in combination with Doxycycline.
Pheneticillin The therapeutic efficacy of Pheneticillin can be decreased when used in combination with Doxycycline.
Carfecillin The therapeutic efficacy of Carfecillin can be decreased when used in combination with Doxycycline.
Propicillin The therapeutic efficacy of Propicillin can be decreased when used in combination with Doxycycline.
Clometocillin The therapeutic efficacy of Clometocillin can be decreased when used in combination with Doxycycline.
Sulbenicillin The therapeutic efficacy of Sulbenicillin can be decreased when used in combination with Doxycycline.
Penamecillin The therapeutic efficacy of Penamecillin can be decreased when used in combination with Doxycycline.
Talampicillin The therapeutic efficacy of Talampicillin can be decreased when used in combination with Doxycycline.
Aspoxicillin The therapeutic efficacy of Aspoxicillin can be decreased when used in combination with Doxycycline.
Metampicillin The therapeutic efficacy of Metampicillin can be decreased when used in combination with Doxycycline.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Doxycycline.
Bismuth subcitrate potassium The serum concentration of Doxycycline can be decreased when it is combined with Bismuth subcitrate potassium.
Strontium ranelate The serum concentration of Doxycycline can be decreased when it is combined with Strontium ranelate.
Calcium glucoheptonate The serum concentration of Doxycycline can be decreased when it is combined with Calcium glucoheptonate.
Calcium glubionate anhydrous The serum concentration of Doxycycline can be decreased when it is combined with Calcium glubionate anhydrous.
Calcium gluconate The serum concentration of Doxycycline can be decreased when it is combined with Calcium gluconate.
Calcium citrate The serum concentration of Doxycycline can be decreased when it is combined with Calcium citrate.
Calcium Phosphate The serum concentration of Doxycycline can be decreased when it is combined with Calcium Phosphate.
Calcium lactate The serum concentration of Doxycycline can be decreased when it is combined with Calcium lactate.
Calcium lactate gluconate The serum concentration of Doxycycline can be decreased when it is combined with Calcium lactate gluconate.
Calcium pangamate The serum concentration of Doxycycline can be decreased when it is combined with Calcium pangamate.
Calcium levulinate The serum concentration of Doxycycline can be decreased when it is combined with Calcium levulinate.
Calcium acetate The serum concentration of Doxycycline can be decreased when it is combined with Calcium acetate.
Calcium chloride The serum concentration of Doxycycline can be decreased when it is combined with Calcium chloride.
Calcium The serum concentration of Doxycycline can be decreased when it is combined with Calcium.
Calcium cation The serum concentration of Doxycycline can be decreased when it is combined with Calcium cation.
Calcium polycarbophil The serum concentration of Doxycycline can be decreased when it is combined with Calcium polycarbophil.
Colestipol Colestipol can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colesevelam Colesevelam can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholestyramine Cholestyramine can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sevelamer Sevelamer can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.

Target Protein

30S ribosomal protein

Referensi & Sumber

Synthesis reference: Dai-Wu Seol, "DNA cassette for the production of secretable recombinant trimeric TRAIL proteins, tetracycline/ doxycycline-inducible adeno-associated virus vector, their combination and use in gene therapy." U.S. Patent US20020128438, issued September 12, 2002.
Artikel (PubMed)
  • PMID: 12684759
    Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, Debrah AY, Pfarr KM, Adjei O, Buttner DW: Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol. 2003 Nov;192(4):211-6. Epub 2003 Mar 5.
  • PMID: 15964448
    Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A: Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet. 2005 Jun 18-24;365(9477):2116-21.
  • PMID: 24284484
    Bernatova S, Samek O, Pilat Z, Sery M, Jezek J, Jakl P, Siler M, Krzyzanek V, Zemanek P, Hola V, Dvorackova M, Ruzicka F: Following the mechanisms of bacteriostatic versus bactericidal action using Raman spectroscopy. Molecules. 2013 Oct 24;18(11):13188-99. doi: 10.3390/molecules181113188.
  • PMID: 21436975
    Valentin S, Morales A, Sanchez JL, Rivera A: Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2009 Aug 12;2:129-40.
  • PMID: 10405705
    Smilack JD: The tetracyclines. Mayo Clin Proc. 1999 Jul;74(7):727-9. doi: 10.4065/74.7.727.
  • PMID: 11381101
    Chopra I, Roberts M: Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001 Jun;65(2):232-60 ; second page, table of contents.
  • PMID: 31751095
    Shutter MC, Akhondi H: Tetracycline .
  • PMID: 32310348
    Patel RS, Parmar M: Doxycycline Hyclate .
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 843 • International brands: 9
Produk
  • Acticlate
    Tablet, coated • 75 mg/1 • Oral • US • Approved
  • Acticlate
    Tablet, coated • 150 mg/1 • Oral • US • Approved
  • Acticlate CAP
    Capsule • 75 mg/1 • Oral • US • Approved
  • Adoxa
    Capsule • 150 mg/1 • Oral • US • Generic • Approved
  • Alodox
    Tablet • 20 mg/1 • Oral • US • Generic • Approved
  • Alti-doxycycline - Tab 100mg
    Tablet • 100 mg / tab • Oral • Canada • Generic • Approved
  • Alti-doxycycline-cap 100mg
    Capsule • 100 mg / cap • Oral • Canada • Generic • Approved
  • Apo-doxy Cap 100mg
    Capsule • 100 mg • Oral • Canada • Generic • Approved
Menampilkan 8 dari 843 produk.
International Brands
  • Doxy — Galpharma
  • Doxycin — Laboratoire Riva
  • Doxylin — Actavis
  • Jenacyclin
  • Microdox — Micro Labs
  • NicAzelDoxyKit
  • Nu-Doxycycline — Nu-Pharm
  • Supracyclin — Grünenthal
  • Vibramycin — Pfizer

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul